Filing identity and reporting period
Important identity discrepancy: The request identifies Tectonic Therapeutic, Inc., but the supplied Form 10-Q is for AVROBIO, Inc. This summary reflects the supplied filing, for the quarter and six months ended June 30, 2020, filed August 6, 2020.
AVROBIO is a clinical-stage gene therapy company developing ex vivo lentiviral therapies for rare diseases. It had no approved products and no product-sales revenue.
Financial performance and liquidity
Amounts below are in millions of U.S. dollars unless stated otherwise. Loss per share is in dollars.
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $20.9 | $12.3 | $39.1 | $24.7 |
| General and administrative expense | $8.0 | $4.3 | $16.3 | $9.6 |
| Total operating expenses | $28.9 | $16.6 | $55.4 | $34.3 |
| Net loss | $28.8 | $16.1 | $54.8 | $33.2 |
| Net loss per share, basic and diluted | $0.80 | $0.67 | $1.57 | $1.38 |
| Operating cash used | Not separately provided for the quarter | $43.5 | $35.7 |
Gross margin is not applicable because there was no product revenue. At June 30, cash and cash equivalents were $244.4 million, current assets $251.0 million, total liabilities $15.8 million and stockholders’ equity $239.8 million. The balance sheet presents no interest-bearing debt. Six-month investing cash use was $1.1 million; financing provided $101.9 million, principally from a February public offering ($93.6 million net) and ATM sales ($8.1 million net). Cash rose $57.3 million over the six-month period.
Changes versus comparable periods
- Q2 net loss widened by $12.8 million year over year; first-half net loss widened by $21.6 million.
- First-half R&D expense increased $14.4 million, driven mainly by personnel and other unallocated costs; G&A rose $6.7 million, reflecting personnel and professional fees.
- Cash from operations used $7.7 million more in the first half than in 2019. Equity financing more than offset operating and investing cash use.
- Interest income declined, primarily because of lower money-market yields.
Outlook, programs, risks and unusual items
- Runway: Management said June 30 cash was expected to fund operating expenses and capital needs into the second half of 2022. The filing cautions that this estimate depends on assumptions and additional funding will eventually be needed.
- Clinical programs: AVR-RD-01 (Fabry) had nine patients dosed across Phase 1 and Phase 2 trials; AVR-RD-04 (cystinosis) had two patients dosed by July 2020; AVR-RD-02 (Gaucher) had its first patient dosed in July 2020. AVR-RD-03 (Pompe) remained preclinical, with IND-enabling work expected to conclude in 2020.
- AVR-RD-01 data: Management reported biomarker and enzyme-activity observations, including reductions in plasma lyso-Gb3 for several Phase 2 patients, but these were interim findings from small studies, not evidence of established clinical benefit. One patient’s kidney biopsy could not be evaluated because of an external laboratory processing error; another patient’s disease variant was not expected to inform certain biopsy endpoints. Skin-biopsy results were described as inconsistent and not clearly correlated with other measures.
- Safety: As of the April 23, 2020 cutoff, no serious adverse events were reported as related to AVR-RD-01 drug product. Reported serious events were attributed to conditioning, disease or pre-existing conditions and had resolved. Small patient numbers and limited follow-up constrain interpretation.
- COVID-19: The pandemic temporarily interrupted or delayed trial dosing, enrollment and some data collection. Dosing had begun to resume at some sites, but management anticipated further delays and could not predict the duration or extent of disruption.
- Financing and commitments: The company expects continuing losses and may need equity, debt, collaboration or other funding. License agreements carry potential milestone and royalty obligations; the filing said no milestone or royalty payments were expected immediately except as disclosed. No material legal proceedings were reported.
- Controls: Disclosure controls were deemed ineffective at June 30, 2020 because previously identified material weaknesses in financial reporting controls had not been fully remediated. Management reported remediation work was ongoing.
- Other developments: The company announced a busulfan monitoring development agreement with Saladax and a conditioning-agent research collaboration with Magenta. It also reported senior leadership transitions and entered a new Toronto office lease.
Most important facts for investors to verify
- Confirm that AVROBIO, rather than Tectonic Therapeutic, is the issuer whose filing is intended.
- Check subsequent clinical-trial disclosures for enrollment, follow-up, endpoint data, safety findings and any regulatory feedback, particularly for AVR-RD-01.
- Assess whether COVID-19 disruptions or development spending changed the stated cash runway into the second half of 2022, and whether further financing was required.
- Review progress in remediating the material weaknesses and whether disclosure controls were later judged effective.
- Monitor execution and comparability of the plato manufacturing platform, clinical supply, and the consequences of the biopsy-processing error.